Abstract
Although speech dysfluencies have been hypothesized to be associated with abnormal function of dopaminergic system, the effects of dopaminergic medication on speech fluency in Parkinson’s disease (PD) have not been systematically studied. The aim of the present study was, therefore, to investigate the long-term effect of dopaminergic medication on speech fluency in PD. Fourteen de novo PD patients with no history of developmental stuttering and 14 age- and sex-matched healthy controls (HC) were recruited. PD subjects were examined three times; before the initiation of dopaminergic treatment and twice in following 6 years. The percentage of dysfluent words was calculated from reading passage and monolog. The amount of medication was expressed by cumulative doses of l-dopa equivalent. After 3–6 years of dopaminergic therapy, PD patients exhibited significantly more dysfluent events compared to healthy subjects as well as to their own speech performance before the introduction of dopaminergic therapy (p < 0.05). In addition, we found a strong positive correlation between the increased occurrence of dysfluent words and the total cumulative dose of l-dopa equivalent (r = 0.75, p = 0.002). Our findings indicate an adverse effect of prolonged dopaminergic therapy contributing to the development of stuttering-like dysfluencies in PD. These findings may have important implication in clinical practice, where speech fluency should be taken into account to optimize dopaminergic therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackermann H, Ziegler W, Oertel WH (1989) Palilalia as a symptom of levodopa induced hyperkinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52:805–807
Akaike A, Ohno Y, Sasa M, Takaori S (1987) Excitatory and inhibitory effects of dopamine on neuronal activity of the caudate nucleus neurons in vitro. Brain Res 418:262–272
Alm PA (2004) Stuttering and the basal ganglia circuits: a critical review of possible relations. J Commun Disord 37:325–369
Anderson JM, Hughes JD, Rothi LJG, Crucian GP, Heilman KM (1999) Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosur Ps 66:776–778
Benke TH, Hohenstein C, Poewe W, Butterworth B (2000) Repetitive speech phenomena in Parkinson’s disease. J Neurol Neurosur Ps 69:319–325
Brady JP (1991) The pharmacology of stuttering: a critical review. Am J Psychiatry 148:1309–1316
Burghaus L, Hilker R, Thiel A, Galldiks N, Lehnhardt FG et al (2006) Deep brain stimulation of the subthalamic nucleus reversibly deteriorates stuttering in advanced Parkinson’s disease. J Neural Transm 113:625–631
Civier O, Bullock D, Max L, Guenther FH (2013) Computational modeling of stuttering caused by impairments in a basal ganglia thalamo-cortical circuit involved in syllable selection and initiation. Brain Lang 196:263–278
Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H et al (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. New Engl J Med 355:896–908
Giraud AL, Neumann K, Bachoud-Levi AC, von Gudenberg AW, Euler HA et al (2008) Severity of dysfluency correlates with basal ganglia activity in persistent developmental stuttering. Brain Lang 104:190–199
Goberman AM, Blomgren M (2003) Parkinsonian speech disfluencies: effects of l-dopa-related fluctuations. J Fluency Disord 28:55–77
Goberman AM, Blomgren M, Metzger E (2010) Characteristics of speech disfluency in Parkinson disease. J Neurolinguist 23:470–478
Ho AK, Bradshaw JL, Iansek R (2008) For better or worse: the effect of levodopa on speech in Parkinson’s disease. Mov Disord 23:575–580
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
Jellinger KA (2012) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 27:8–30
Kim H, Hasegawa-Johnson M, Perlman A (2011) Vowel contrast and speech intelligibility in dysarthria. Folia Phoniatr Logop 63:187–194
Koller WC (1983) Dysfluency (stuttering) in extrapyramidal disease. Arch Neurol 40:175–177
Leder SB (1996) Adult onset of stuttering as a presenting sign in a parkinsonian-like syndrome: a case report. J Commun Disord 29:471–478
Logemann JA, Fisher HB, Boshes B, Blonsky ER (1978) Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J Speech Hear Res 43:47–57
Louis ED, Winfield L, Fahn S, Ford B (2001) Speech dysfluency exacerbated by levodopa in Parkinson’s disease. Mov Disord 16:562–581
Maguire GA, Yu BP, Franklin DL, Riley GD (2004) Alleviating stuttering with pharmacological interventions. Expert Opin Pharmaco 5:1565–1571
Nebel A, Reese R, Deuschl G, Mehdorn HM, Volkmann J (2009) Acquired stuttering after pallidal brain stimulation for dystonia. J Neural Transm 116:167–169
Rusz J, Cmejla R, Ruzickova H, Ruzicka E (2011) Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. J Acoust Soc Am 129:350–367
Rusz J, Cmejla R, Tykalova T, Ruzickova H, Klempir J et al (2013) Imprecise vowel articulation as a potential early marker of Parkinson’s disease: effect of speaking task. J Acoust Soc Am 134:2171–2181
Sapir S, Spielman JL, Ramig LO, Story BH, Fox C (2007) Effects of Intensive Voice Treatment (the Lee Silverman Voice Treatment [LSVT]) on Vowel Articulation in Dysarthric Individuals With Idiopathic Parkinson Disease: acoustic and Perceptual Findings. J Speech Lang Hear R 50:899–913
Sapir S, Ramig LO, Fox C (2008) Speech and swallowing disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg 16:205–210
Shahed J, Jankovic J (2001) Re-emergence of childhood stuttering in Parkinson’s disease: a hypothesis. Mov Disord 16:114–118
Skodda S, Gronheit W, Schlegel U (2012) Impairment of vowel articulation as a possible marker of disease progression in Parkinson’s disease. PLoS ONE 7:e32132
Teesson K, Packman A, Onslow M (2003) The Lidcombe behavioral data language of stuttering. J Speech Lang Hear R 46:1009–1015
Thiriez C, Roubeau B, Ouerchefani N, Gurruchaga JM, Palfi S et al (2013) Improvement in developmental stuttering following deep brain stimulation for Parkinson’s disease. Parkinsonism Relat D 19:383–384
Watkins KE, Smith SM, Davis S, Howell P (2008) Structural and functional abnormalities of the motor system in developmental stuttering. Brain 131:50–59
Williams GV, Castner SA (2006) Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 139:263–276
Wu JC, Maguire G, Riley G, Lee A, Keator D et al (1997) Increased dopamine activity associated with stuttering. NeuroReport 8:767–770
Acknowledgments
The authors thank to doctors Veronika Majerova and Jana Picmausova for provision of clinical data and to Aaron Rulseh for his thoughtful English correction. This project was supported by the Czech Science Foundation (GACR 102/12/2230) and Charles University in Prague (PRVOUK-P26/LF1/4).
Conflict of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tykalová, T., Rusz, J., Čmejla, R. et al. Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm 122, 1135–1142 (2015). https://doi.org/10.1007/s00702-015-1363-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-015-1363-y